A replay of the call will be available starting on August 3, 2016 through August 10, 2016. To access the replay, dial (877) 344-7529 for domestic callers and (412) 317-0088 for international callers, with the replay access code 10090361. The webcast replay will be available in the investor relations section of the Company's website for 90 days following the completion of the call and a transcript will be posted to the investor relations website.
Based near Atlanta, Georgia, EndoChoice® (NYSE: GI) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The Company was founded in 2008 and has rapidly developed a broad and innovative product portfolio, which includes the Full Spectrum Endoscopy® (Fuse®) system. EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice, Inc.
David Gill, President & Chief Financial Officer
Nick Laudico or Zack Kubow
The Ruth Group
646-536-7030 / 7020
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/endochoice-to-report-second-quarter-2016-financial-results-on-august-3-2016-300304500.html